GS-4182, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-1720 clinical trials

An Operationally Seamless Phase 2/3, Randomized, Active Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination with GS-4182 Versus Biktarvy in Treatment Naive People with HIV-1

This study is testing new medicines for people recently diagnosed with HIV-1. It compares a weekly pill combining GS-1720 and GS-4182 against a daily pill called Biktarvy. The main goal is to see which treatment best controls the virus.